Effect of salpingectomy in women undergoing hysterectomy.
Phase 3
- Conditions
- terine bleeding.Irregular menstruation, unspecified
- Registration Number
- IRCT20170513033941N46
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 86
Inclusion Criteria
Premenopausal women aged 30 to 50 years who are undergo hysterectomy referred to shabihkhani clinic.
No menopause symptoms
FSH<10 IU.
Exclusion Criteria
A history of pelvic surgery
Existence of ovarian mass in sonography before the surgery
smoking
OCP consumption at least for 6 months.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum anti-mullerian hormone levels. Timepoint: Before surgery and 3 months after intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method FSH serum level. Timepoint: Before surgery and 3 months after intervention. Method of measurement: Elisa kit.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does salpingectomy affect ovarian reserve via molecular pathways in IRCT20170513033941N46 phase III trial for hysterectomy?
What is the comparative effectiveness of salpingectomy versus oophorectomy in preserving ovarian reserve in IRCT20170513033941N46 phase III trial?
Do AMH or inhibin B levels serve as biomarkers for predicting ovarian reserve preservation after salpingectomy in IRCT20170513033941N46?
What adverse events are reported in IRCT20170513033941N46 salpingectomy trial for hysterectomy patients and how are they managed?
How does salpingectomy in IRCT20170513033941N46 influence the use of hormone replacement therapy post-hysterectomy in women with irregular menstruation?